Australia's Alterity Therapeutics soars on trial nod for Parkinson's drug
14/12/2021 03:31
** Shares of Alterity Therapeutics Ltd ATH.AX jump as much
as 10.9% to A$0.026, set to gain most since Nov 4
** Drug developer says it got phase 2 clinical trial
approval from The New Zealand Medicines and Medical Safety
Authority (Medsafe) for its Parkinson's disease treatment drug,
ATH434 urn:newsml:reuters.com:*:nASX6jjN2Q
** Co says it will initiate study in Q1 next year
** Stock hits highest since Nov 30
** As of Monday's close, stock had dropped 25.8% this year
(Reporting by Navya Mittal)
((Navya.Mittal@thomsonreuters.com;))
Recent news on Alterity Therapeutics
See all newsBrief: Alterity Therapeutics Achieves Alignment With U.S. FDA On Pivotal Phase 3 Program For Ath434 In Multiple System Atrophy
Brief: Alterity Therapeutics Receives Positive FDA Feedback On Ath434 Phase 3 Program
Brief: Alterity Therapeutics Says Julian Barbaczy Appointed Non-Exec Chair
Brief: Alterity Therapeutics Raises A$20.0 Million In Strategic Placement
Brief: Alterity Therapeutics Ltd Raises A$20 Million In Capital